{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:28:16Z","timestamp":1773275296889,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T00:00:00Z","timestamp":1165449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> The American consensus statement on patients with low\u2010risk thyroid cancer, published in 2003, suggests repeat <jats:sup>131<\/jats:sup>I therapy if the thyroglobulin value is elevated at first follow\u2010up. We evaluated this strategy in our practice.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Among 407 patients with thyroid cancer who had total thyroidectomy and <jats:sup>131<\/jats:sup>I ablation between January 2000 and December 2003, 12 patients with stage I thyroid cancer (any tumour (T), any node (N), metastasis (M)0 if\u00a0&lt;\u00a045 years or T1, N0, M0 if\u00a0&gt;\u00a045\u00a0years), were re\u2010treated on the basis of their thyroglobulin level at first follow\u2010up. Mean patient age was 32\u00b78\u00a0years. None of them had a T4 tumour. Thyroglobulin levels after thyroid hormone withdrawal \u2018off\u2010T4\u2019 ranged between 4\u00b75 and 251\u00a0ng\/ml (median 8). One to four courses of 3\u00b77 GBq <jats:sup>131<\/jats:sup>I were given.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Three patients had a negative <jats:sup>131<\/jats:sup>I therapy scan and an uneventful course. Two patients had slight residual uptake only in the thyroid bed and negative ultrasound examination. Four patients had isolated <jats:sup>131<\/jats:sup>I uptake in the mediastinal region. No abnormalities were found on complementary mediastinal imaging. This finding was interpreted as benign <jats:sup>131<\/jats:sup>I thymic uptake. The last three patients also had mediastinal thymic uptake associated with a slight thyroid bed uptake. One patient had a gradual increase in the thyroglobulin level, and underwent resection of nonfunctioning neck lymph nodes. Thyroglobulin levels declined in all other patients.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> No distant lesions were found in a group of young \u2018low\u2010risk\u2019 thyroid cancer patients given empirical <jats:sup>131<\/jats:sup>I therapy for residual thyroglobulin. When blind <jats:sup>131<\/jats:sup>I therapy shows no uptake, or uptake limited to the thymus, <jats:sup>131<\/jats:sup>I therapy should not be repeated. The authors also briefly discuss the hypothesis that enhanced thymus might be a source of benign thyroglobulin secretion.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2006.02731.x","type":"journal-article","created":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T13:28:34Z","timestamp":1165498114000},"page":"329-334","source":"Crossref","is-referenced-by-count":11,"title":["Should \u2018low\u2010risk\u2019 thyroid cancer patients with residual thyroglobulin be re\u2010treated with iodine 131?"],"prefix":"10.1111","volume":"66","author":[{"given":"Elif","family":"Hindi\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Zanotti\u2010Fregonara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Duron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Yves","family":"Devaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021702"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.273"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480589"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000443"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500105"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.109"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02158"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050217"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02261249"},{"key":"e_1_2_6_11_2","first-page":"1830","article-title":"Iodine concentration by the thymus in thyroid carcinoma","volume":"37","author":"Vermiglio F.","year":"1996","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-199908000-00011"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20725"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050526"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050264"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0986"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1929-2"},{"key":"e_1_2_6_18_2","first-page":"1464","article-title":"Clinical impact of 18F\u2010FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy","volume":"42","author":"Helal B.O.","year":"2001","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.9.7831"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021365"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0492"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","unstructured":"D\u00f6bert N. Menzel C. Oeschger S.&Grunwald F.(2004) Differentiated thyroid carcinoma: the new UICC6th editionTNM classification system in a retrospective analysis of 169 patients.Thyroid 14 65\u201370.","DOI":"10.1089\/105072504322783867"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1174-5"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711020408"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119032"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.879"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1998.0210"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.4049\/jimmunol.161.11.5918","article-title":"Transcription of a broad range of self\u2010antigens in human thymus suggests a role for central mechanisms in tolerance toward peripheral antigens","volume":"161","author":"Sospedra M.","year":"1998","journal-title":"Journal of Immunology"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.133"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050530"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(01)01077-3"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031677"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.14.6707"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni723"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18903.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0019-2805.2003.01804.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115601"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/35018111"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2006.02731.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2006.02731.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:29:58Z","timestamp":1697185798000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2006.02731.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,15]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1111\/j.1365-2265.2006.02731.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02731.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,15]]}}}